Navigation Links
Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.

All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.

Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.

The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.

Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities, Dahabreh said.

This is the first meta-analysis of current published trials on the adjuvant use of trastuzumab. The results are of great clinical value since they indicate that treatment with trastuzumab results in major survival benefit in women with an aggressive disease subtype.

The level of effectiveness demonstrated by this ana lysis is largely unprecedented in the treatment of solid tumors, the authors say, and highlights the potential of implementing targeted agents with cytotoxic chemotherapy.

More information about ECLU is available at http: www.esmo.org/activities/ecluconference/.


'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Combination Therapy Found To Improves Stroke Recovery
10. Combination Therapy Found To Be More Effective In Treating Brain Cancer
11. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... at the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, ... , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... as well as Palm Desert, is opening a new office in San Clemente, ... transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with major ...
(Date:1/17/2017)... ... 17, 2017 , ... Medic-CE , a Career Step ... has released four new continuing education courses as part of its Code3 CME ... online classroom and meet the requirements of the National Continued Competency Program (NCCP), ...
(Date:1/17/2017)... ... 17, 2017 , ... Surgeons from New York’s fastest growing ... on the latest breakthroughs in the prevention, diagnosis and treatment of the most ... eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and Managing ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Seno Medical Instruments, Inc. ... breast cancer through the development of an opto-acoustic (OA/US) ... Miller as SVP of Engineering. Mr. Miller previously ... FUJIFILM SonoSite, with headquarters in Bothell, Washington ... his 30-year career to the development of innovative medical ...
(Date:1/18/2017)... Jan. 18, 2017  Tarix Orphan LLC today announced ... a Rare Pediatric Disease (RPD) designation for the company,s ... Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There ... is limited to supportive care. "The RPD ... Designation previously granted by the FDA in this indication," ...
(Date:1/18/2017)... January 18, 2017 After the recent ... the use of cannabis both for medical and recreational purposes ... Americans open to the use of cannabis, but the focus ... to Arcview Market Research, the North American legal cannabis market ... the previous year. The research projects sales will grow at ...
Breaking Medicine Technology: